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Abstract 
Iron-supplements are widely consumed; however most of the iron is not absorbed and enters the 
colon where potentially pathogenic bacteria can utilise it for growth. This study investigated the 
effect of iron availability on human gut microbial composition and function using an in vitro colonic 
fermentation model inoculated with faecal microbiota from healthy adult donors, as well as 
examining the effect of iron on the growth of individual gut bacteria. Batch fermenters were seeded 
with fresh faecal material and supplemented with the iron chelator, bathophenanthroline 
disulphonic acid (BPDS). Samples were analysed at regular intervals to assess impact on the gut 
bacterial communities.  The growth of Escherichia coli and Salmonella Typhimurium was significantly 
impaired when cultured independently in iron-deficient media. In contrast, depletion of iron did not 
affect the growth of the beneficial species, Lactobacillus rhamnosus, when cultured independently. 
Analysis of the microbiome composition via 16S-based metataxonomics indicated that under 
conditions of iron chelation, the relative abundance decreased for several taxa, including a 10% 
decrease in Escherichia and a 15% decrease in Bifidobacterium. Metabolomics analysis using 1 H-
NMR indicated that the production of SCFAs was reduced under iron-limited conditions. These 
results support previous studies demonstrating the essentiality of iron for microbial growth and 
metabolism, but, in addition, they indicate that iron chelation changes the gut microbiota profile and 
influences human gut microbial homeostasis through both compositional and functional changes.  
Keywords: chelation; dysbiosis; gut microbiota; Iron; short chain fatty acids 
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1. Introduction 
Humans are host to a wide variety of microbes which develop  ecosystems that are specific to any 
one individual but which are subjected to a life-long process of colonisation by foreign microbes [1]. 
Through evolution, an environment of mutualism has been created whereby many host-bacterial 
associations have become beneficial relationships; such as is found in the large intestine (colon), 
which is home to the highest number of microbes (> 100 trillion bacteria) in our body. Commensal 
bacteria of the mammalian gut have long been recognised for the advantages they confer to the 
host. The benefits include defence against opportunistic pathogens, metabolism of indigestible 
compounds, provision of essential nutrients and an involvement in the development of the intestinal 
structure [2, 3], whilst also producing metabolites, such as SCFAs that contribute towards providing 
energy to host cells [4-6]  The human gut microbiome also contributes towards the basic 
developmental features and functions of the immune system [7]. Conversely, perturbations (e.g. 
antibiotic treatment and/or overgrowth of pathogenic bacteria) in these symbiotic relationships, 
termed dysbiosis, can lead to a negative impact on the host’s health [8]. Dysbiosis has been 
associated with a range of human disease states, such as autoimmune disorders [9], [10] increased 
vulnerability to cancers [11], irritable bowel syndrome [12-15], and obesity [16], and research on 
these associations, including an understanding of the mechanisms involved, is a high priority. The 
number of studies examining the relationship between diet and the gut microbiome has increased 
over the past years and has shown that the gut microbiome composition and metabolism are 
significantly affected by diet [17]. 
Iron, an essential nutrient for humans, is highly abundant in the environment and involved in 
numerous biological processes such as hydrogen production, respiration, and DNA biosynthesis. It 
also functions as a co-factor in numerous metabolic pathways within a host cell and is essential for 
nearly all prokaryotic and eukaryotic cells. In humans, the absorption of iron by the epithelial cells of 
the small intestine is a very tightly regulated process due to the absence of excretory pathways [18]. 
The efficiency of absorption depends on the potential availability of iron in the diet, and is regulated 
by physiological iron requirements, including body iron stores, with hepcidin having a central role in 
the control of absorption [19].  
 
Dietary iron has been broadly classified into two types, non-haem and haem iron. Both forms of 
dietary iron have a separate pathway of uptake by enterocytes, where haem iron is better absorbed 
(25-30%) compared to the poorly absorbed non-haem iron, (0-15% absorbed) despite being the 
most common form of iron present in the diet [20]. The unabsorbed iron travels to the large 
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intestine, and there is accumulating evidence to suggest that this unabsorbed colonic iron can 
facilitate the growth of intestinal pathogens [21].  
The vast majority of bacteria in the gut require iron for growth and development, and they have 
formulated many strategies to acquire this nutrient, which in its more common state (Fe3+) has low 
or zero solubility. Potentially pathogenic bacteria make use of a continuous supply of micronutrients, 
such as iron, for metabolism and replication. Thus, there is constant competition for iron between 
various bacteria, many of which have developed mechanisms, such as siderophore production, to 
acquire iron, particularly when availability is limited. Unlike most bacteria, members of the 
Bifidobacteriaceae and Lactobacilliaceae families (two families that are believed to be beneficial to 
the host [22-25]) have a very limited need for iron [26]. Lactobacilli do not produce siderophores to 
sequester iron, and their growth is similar in media with and without iron [27]. Bifidobacterium 
breve, an important member of the Bifidobacterial species in breast-fed infants, can acquire luminal 
iron with the help of a divalent metal permease, however, many of the Bifidobacterium species do 
not synthesise siderophores or other forms of iron-carriers. The human body has created many ways 
to promote the growth of these beneficial bacteria, such as the presence of lactoferrin in breast milk 
which travels intact to the large intestine [28-30], which with its high affinity for iron, renders the 
iron unavailable to potentially pathogenic bacteria [31]. Along with high amounts of dietary iron in 
the gut lumen, the oral administration of iron supplements also results in freely available “unbound” 
iron in the colon [32-34]. This disturbs iron homeostasis consequently modifying the gut microbial 
composition [35-37]. 
An emerging link between the gut microbiome and iron availability has been observed, however 
several studies that have investigated the effects of iron on the human gut microbiota are mainly 
focussed on the infant microbiome [6, 33-35, 38-40]. Other studies have looked at the role of iron in 
the gut microbiota in individuals with either metabolic [41] or iron disorders and therefore, this 
study was designed to use in vitro colon models that mimic the microbiological conditions of the 
human large intestine to assess the impact of iron limitation on structure and function of the 
complex gut bacterial communities of healthy adults. 
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2. Materials and Methods 
2.1 Bacterial strains and growth conditions 
To evaluate the role of iron on bacterial growth, the following bacterial strains were chosen: 
Escherichia coli 1BO4 (isolated from human faeces), Bifidobacterium longum B78 F110564 (isolated 
from human faeces), Lactobacillus rhamnosus GG F111027, Salmonella Typhimurium (ATCC SL1344), 
Clostridium perfringens (NCTC 3110) and Bacteroides thetaiotaomicron VP1-5482 (ATCC 29148). 
Bacteria were cultured in the following media: Luria (L) Broth (E. coli and S. Typhimurium); Brain 
Heart Infusion (BHI; B. longum); BHI supplemented with vitamin K (0.5% v/v), hemin (0.5mg/mL), 
resazurin (0.02% w/v) and L-cysteine (0.5g/L) (C. perfringens) and BHI with hemin (B. 
thetaiotaomicron); De Man, Rogosa and Sharpe (MRS) supplemented with glucose (L. rhamnosus). 
All bacteria were grown under anaerobic conditions at 37oC. E. coli and S. Typhimurium were 
agitated at medium speed throughout the growth period, whilst the remaining bacteria were grown 
under static conditions.  
 
2.2 The effect of iron chelation on bacterial pure cultures  
Bacterial cultures were grown overnight in rich media specified above. Cultures were seeded in 100-
well honeycomb plates and cells were then provided with bathophenanthrolinedisulfonic acid 
disodium salt hydrate (BPDS; B1375, Sigma, United Kingdom) at final concentrations ranging from 0 
– 50 μM.  Samples were analysed using a Magellan™ Microplate Reader (Tecan Life Sciences, 
Switzerland), which monitors the growth of microorganisms by measuring the turbidity of the 
culture (optical density, OD600) of the liquid growth medium. The experiments were run for 24 h, 
with OD600, taken every 10 minutes. The experiments were performed at 37
oC under anaerobic 
conditions. 
2.3 In vitro colonic fermentations 
10 g of fresh fecal samples obtained from healthy volunteers were diluted 1:10 in deoxygenated 
phosphate buffered saline (pH 7.7), and homogenised using a Stomacher 400 (Seward, United 
Kingdom) at 230 rpm for 45 s. All samples were processed within 4 h of stool collection.  
The working volume of each vessel was set at 150 mL, of which 15 mL was processed faecal inocula 
and 135 mL was nutritive media (peptone water 2 g/l, yeast extract 2 g/l, NaCl 0.1 g/l, K2HPO4 0.04 
g/l, KH2PO4 0.04 g/l, MgSO4.7H2O 0.01 g/l, CaCl2.6H2O 0.01 g/l, NaHCO3 2 g/l, Tween 80 2 ml, glucose 
10 g/l, vitamin K1 10 μl, cysteine HCl 0.5 g/l, bile salts 0.5 g/l, pH 7.0). The pH was controlled and 
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maintained between 6.6 - 7.0 using pH control units Fermac 260 (Electrolab, United Kingdom), 
connected to 1M NaOH and 1M HCL solutions. Vessels were kept at 37oC by a circulating water 
jacket and anaerobiosis was maintained by continuous bubbling of the system with oxygen-free 
nitrogen gas. Conditions tested were either nutritive media with faecal inocula only (Control), or 
with faecal inocula and BPDS (70 μM). The concentration of BPDS was chosen as a result of 
preliminary experiments investigating the baseline faecal iron concentrations in multiple healthy 
donors (data not shown). We used 70 µM BPDS as we calculated that this concentration would be 
sufficient to chelate most of the iron in the colon. Per donor, 1 vessel was used for each condition. 
Samples were taken at 0, 4, 8, and 24 h from each vessel, serially diluted in PBS and enumerated on 
selective agar plates [42]. Faecal samples used in the colon model experiments were obtained from 
participants recruited onto the QIB Colon Model study. Men and women aged 18 years or older who 
live or work within 10 miles of the Norwich Research Park were recruited onto the QIB Colon Model 
study if they satisfied the following criteria. Participants who were assessed to have a normal bowel 
habit, regular defecation between three times a day and three times a week, with an average stool 
type of 3 – 5 on the Bristol Stool Chart, and no diagnosed chronic gastrointestinal health problems, 
such as irritable bowel syndrome, inflammatory bowel disease, or coeliac disease were eligible to 
enrol onto the study. Demographic information was collected, and a brief health questionnaire was 
completed during the eligibility screening. Participants were asked additional questions immediately 
prior to donating a stool sample to confirm that they had not taken antibiotics or probiotics within 
the last four weeks, had not experienced a gastrointestinal complaint, such as vomiting or diarrhoea, 
within the last 72 hours, were not currently pregnant or breast-feeding, had not recently had an 
operation requiring general anaesthetic, and were not taking iron or multivitamin supplements. The 
study was approved by the Quadram Institute Bioscience (formally Institute of Food Research) 
Human Research Governance committee (IFR01/2015), and London - Westminster Research Ethics 
Committee (15/LO/2169). The informed consent of all participating subjects was obtained, and the 
trial is registered at http://www.clinicaltrials.gov (NCT02653001). 
2.4 DNA extraction for 16S rDNA based metagenomics 
DNA was extracted from all samples collected from in vitro colonic fermentations using a 
commercially available kit (FastDNA spin kit for soil; MP Biomedicals, USA, Cat No. 6560200). 
Samples were thawed on ice, homogenized, and approximately 200 mg of each were used to extract 
DNA following manufacturer's instruction, with an additional bead beating step using FastPrep (MP 
Biomedicals, USA), as previously described by Kellingray et al., [43]. 
2.5 16S rRNA gene amplification and sequencing 
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The impact of iron on the composition of the human gut microbiome was investigated using high 
throughput 16S rRNA gene (V4 region) sequencing using the Illumina Miseq platform, followed by 
data analysis using the Quantitative Insights into Microbial Ecology (QIIME, V1.9) pipeline. Each 
sample sequence was filtered to read lengths between minimum 200 and maximum 1,000 bp. 
ChimeraSlayer was used to filter trimmed reads for chimeric sequences after which Shannon index 
were used to create alpha diversity plots. Weighted UniFrac data were used to produce beta 
diversity PCoA plots, using the XLSTAT add-on package on Microsoft Excel.  
2.6 Short chain fatty acid quantification in cultured microbiomes 
Faecal water was prepared to quantify short chain fatty acids in stool. Briefly, samples (13 mL) taken 
from colonic batch fermentations were centrifuged at 3220 xg for 15 minutes at 4oC. 100 μL NMR 
buffer (0.26 g NaH2PO4 and 1.41 g K2HPO4 made up in 100 ml D2O, containing 0.1% NaN3 (100 mg), 
and 1 mM sodium 3-(Trimethylsilyl)-propionate-d4, (TSP) (17 mg) as a chemical shift reference) was 
added to 900 µL supernatant and analysed using 1H NMR spectroscopy (this mixture is defined as 
‘faecal water’). The 1H NMR spectra were recorded at 600 MHz on a Bruker Avance spectrometer 
(Bruker BioSpin GmbH, Germany) running Topspin 2.0 software and fitted with a cryoprobe and a 
60-slot autosampler. Each 1H NMR spectrum was acquired with 256 scans, a spectral width of 12,300 
Hz, and an acquisition time of 2.67 seconds. The “noesypr1d” pre-saturation sequence was used to 
suppress the residual water signal with a low-power selective irradiation at the water frequency 
during the recycle delay and a mixing time of 10 ms. Spectra were transformed with a 0.3 Hz line 
broadening, and were manually phased, baseline corrected, and referenced by setting the TSP 
methyl signal to 0 ppm. The metabolites were quantified using the software Chenomx® NMR Suite 
7.0TM. 
2.7 Quantification of iron levels in fermentation samples 
A 20 µL aliquot of the faecal water prepared in section 2.6 was used to quantify iron concentrations 
of the fermentation samples at 0, 8 and 24 h using the ferrozine assay as per manual instructions 
(Iron Assay Kit ab83366, Abcam, UK). Briefly, iron in the sample is reduced using an Fe reducer, 
provided by the kit, after which iron reacts with Ferene S (an iron chromogen) to produce a stable 
coloured complex. Absorbance measurements were taken at 593 nm. 
2.8 Statistical analysis 
Data from pure culture experiments and in vitro colonic fermentations were expressed as means ± 
standard errors of the means (SEM). Pure cultures were analysed using one-way ANOVA followed by 
Bonferroni post-tests with GraphPad Prism software (Version 5.04), whilst in vitro colonic batch 
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fermentations were analysed using unpaired t-tests assuming unequal variances on Microsoft Excel. 
P<0.05 was considered statistically significant.  
 
 
 
3. Results 
3.1 Iron chelation significantly reduced the growth of selected bacterial species grown in pure 
cultures 
For pure culture experiments, we wanted to test a range of gut bacteria that are known to be 
affected or unaffected by iron, but the selection, to some extent, depended on what was available in 
the laboratory. Therefore, various bacterial species were treated with different concentrations (0, 
10, 20, and 50 µM) of BPDS in triplicate for 24 h to determine the effect of iron chelation on their 
growth. A dose-dependent reduction in the growth of E. coli, S. Typhimurium and B. 
thetaiotaomicron (p<0.0001), were observed in the presence of BPDS, at 24 h (Fig 1 A-C). As 
expected, L. rhamnosus, a bacterial species known to be able to grow in the absence of iron, 
exhibited comparable growth to the BPDS-free (0 µM) culture, confirming previous observations that 
iron is not an essential nutrient for the survival of this bacterial species (Fig 1 E). A decrease was also 
observed in the growth of B. longum (p<0.01) upon iron chelation (Fig 1 D). These results support 
the idea that iron is an essential nutrient for bacteria, and in its absence the growth of many bacteria 
is restricted.  
3.2 Reduced iron availability decreased the growth of potentially pathogenic bacteria under in 
vitro colonic fermentation conditions 
Batch fermentations were performed for 24 h to elucidate the effects of iron depletion on the 
human gut microbiome by enumerating specific bacterial groups using selective agar plates. Counts 
from the control vessel of the three individual experiments were first normalised to 100% and 
thereafter, viable counts from the iron-chelated vessels were shown as percentages in relation to 
the Control. Finally, the data from the three individual experiments were combined and average 
percentages (±SEM) presented (Table 1). Results showed a decrease in the viable counts of a 
number of bacterial groups, including Enterobacteriaceae (p<0.05 at 8 and 24 h), Bifidobacteria 
(p<0.001 at 8 h) and Lactobacilli (p<0.01 at 8 and 24 h), upon iron chelation at 8 h and 24 h (Table 1). 
It should be noted that the high viable counts of Bifidobacteria at 24 h is attributed to a single donor. 
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The remaining two donors displayed a substantial reduction in the viable counts of Bifidobacteria 
under iron-chelated conditions. 
3.3 16S rRNA gene sequencing revealed a decrease in the relative abundance of potentially 
pathogenic bacterial genera in response to iron limitation 
High-throughput paired-end sequencing of the 16S rRNA gene (V4 region) was performed on 
fermentation samples using the Illumina Miseq platform, and microbial communities present in 
relative abundances ≥0.5% are illustrated in Fig 2. After combining and averaging the abundance 
values from the three individual experiments, the data revealed that the most abundant genera at 0 
h were Escherichia (16.1%), followed by Bacteroides (8.7%), (Fig 2, SEM values can be found in Table 
2). It is worth noting that the relative abundance of Escherichia is entirely attributed to one donor 
only, as the remaining two donors had no more than 0.1% Escherichia present at T0. 
Briefly, the relative abundance of Escherichia was reduced substantially in the iron chelated 
fermentation vessel in comparison to the control vessel at 8 h (0.8% vs 10.7%) and 24 h (2.3% vs 
5.3%) (Fig 2). This correlates well with the reduction in the viable counts for Enterobacteriaceae 
(Table 1). Again, it is worth noting that the high relative abundance of Enterobacteriaceae at T8 and 
T24 for both control and chelator conditions, is entirely attributed to the levels observed in one 
donor only, since in the other two donors, the levels were below the detectable limit. A similar trend 
was observed for Bifidobacterium, where the relative abundance was much lower at T8 and T24 
under iron-chelated conditions (4.1% vs 15% and 14% vs 29%, respectively), which is also reflected in 
the viable counts results for Bifidobacteria at 8 h. Interestingly, 16S rDNA analysis indicated that at 
24 h, the relative abundance of Streptococcus increased to 36% in the iron chelated condition 
compared to the starting proportion of 4.7%. Iron-depleted conditions have been shown to 
proportionally decrease many bacterial groups, and this may provide other bacteria, such as 
Streptococcus, with a competitive advantage resulting in their increased growth. This could also be 
true for Bacteroides, as the relative abundances of this genus increased at both 8 h (10.6% to 18.1%) 
and 24 h (2.7% to 4.4%) under iron chelated conditions. Finally, 16S rDNA analysis indicated that 
Clostridium abundance was largely unaffected by iron removal (Fig 2), and this was reflected in the 
viable counts for Clostridia (Table 1). 
3.4 Iron chelation resulted in a shift in bacterial diversity profiles 
Alpha (α) – and beta (β) – diversity was measured for all in vitro colonic fermentation samples 
tested. The Shannon index, which is a measure of α- diversity, showed a minimal difference in 
diversity within the population in the absence of the chelator (Fig 3a). However, an increase in 
population diversity was observed at 8 h in the presence of BPDS. The principal coordinates analysis 
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(PCoA) plot (Fig 3b), using the weighted UniFrac metric, which depicts β- diversity, indicates that the 
microbiotas of the subjects before and after iron chelation did not have a large range of taxa in 
common. Interestingly, at both 8 h and 24 h, a shift in β-diversity was observed upon iron chelation 
when compared to the control at the respective time points, depicted by the dashed line. 
3.5 Levels of short chain fatty acids decrease upon iron chelation during in vitro colonic 
fermentation 
1H-NMR spectroscopy was used to determine the levels of over 70 metabolites from samples taken 
from the fermenters at 0, 8, and 24 hr. The three metabolites which showed the most substantial 
changes between treatments, were the short chain fatty acids (SCFAs), acetate, propionate and 
butyrate (Fig 4). 
Acetate concentrations was ~25.3 mM under control conditions (i.e. 0 μM BPDS) at 8 h with lower 
levels (~6.3 mM) found when iron was chelated (with 70 µM BPDS) at the same time-point. The 
same trend was observed at 24 h where acetate concentrations were ~33.3 mM in the control vessel 
whereas under iron-limitation, its levels were reduced to ~25.6 mM. Levels of propionate and 
butyrate exhibited the same pattern under control and iron-chelated conditions. In the control 
condition, ~1.1 mM (8 h) and ~6.8 mM (24 h) of butyrate was measured whereas under iron-
chelation, butyrate levels were reduced (~0.4 mM at 8h and ~3.6 mM 24 h) representing 47% 
reduction at 24 h. This is reflected in the reduction observed for the relative abundances of the 
members of the Ruminococcus (3.9% to 1.5%) genera, which are common butyrate producers.  
Although similar propionate levels were observed between the different conditions at 8 h, 
propionate concentrations were lower in the iron-chelated vessel compared to the control at 24 h 
(~10.5 mM vs ~3.5 mM). This represents a 67% decrease in production at 24 h under iron-limiting 
conditions. This is in line with the 70% decrease observed in the viable counts of Bacteroides (a 
genus containing propionate producers) under low iron conditions (Table 1). 
4. Discussion 
Iron supplements are consumed widely, but the majority of the iron passes through to the colon 
where it can be utilised by iron-requiring bacteria. This study was designed to assess the effects of 
colonic iron chelation on the human gut microbiota. We found that the addition of BPDS, a chemical 
iron chelator, significantly reduced the growth of E. coli, S. Typhimurium, B. thetaiotaomicron and B. 
longum (Figure 1). These results confirm well-established knowledge that iron promotes the growth 
of potentially pathogenic bacteria. However, Cronin et al., [44] reported that the growth of two B. 
longum strains were largely unaffected in the presence of an iron chelator, even at the highest 
chelator concentration (5 µM), suggesting that the effect of iron chelation on Bifidobacteria could be 
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largely strain-dependent.  In the same study [44], no effect on the growth of L. rhamnosus was 
observed and it is known that Lactobacillus does not require iron for growth due to an absence of 
haem-containing enzymes. However, they can substitute other metals for iron, such as cobalt and 
manganese  [45], which may give these bacteria a competitive advantage in low-iron conditions.  
The net effects of iron on the gut microbial composition are still inconclusive and need further 
research as the results reported are inconsistent [6, 39, 44, 45]. Our study showed a marked effect 
on the global microbiome composition when iron was chelated in the fermentation media with BPDS 
(Figure 2). BPDS acts as a chelator of various metals and, in particular, it has been shown to bind iron 
with very high affinity and has therefore been used as an iron chelator in many studies [46, 47].  
Comparison of the relative abundance of bacterial taxa between the two conditions (control and 
BPDS) illustrated that the most apparent differences were the decreased relative abundance of the 
potentially pathogenic Escherichia. The observed decrease of Bifidobacterium is interesting as other 
studies have reported different outcomes, which could be due to strain specificity, inter-individual 
variability of the host, as well as the effects of neighbouring taxa and metabolites. However, the 
relative abundance of Clostridium remained relatively stable, which has been observed in other 
studies. Notably, Streptococcus, a member of the lactic acid bacteria group to which Lactobacillus 
also belongs, was seen to increase upon iron removal, and this could potentially lead to restricted 
growth of other bacteria in the gut environment. 
Studies investigating the effects of iron supplementation report comparable results to those found 
in this study in relation to the relative abundance of various bacterial taxa, including Escherichia. 
One study examined the effects of low and high doses of in-home iron supplementation on the gut 
microbiome of Kenyan children [39]. In this setting, provision of iron-fortified porridge led to an 
increase in pathogen abundance, with proportions of Enterobacteria, Clostridium and E. coli 
increasing, whilst Bifidobacteria decreased. In addition, children given iron-fortified porridge had 
elevated levels of faecal calprotectin, a marker of gut inflammation, which is likely to reflect an 
increased pathogenic profile.  
Much of the published literature focuses on the effects of iron on the infant microbiome which may 
not be the same as adults. In addition, geographical location is probably important, as studies have 
shown that individuals from developing countries tend to have a greater pathogenic microbial 
profile due to the lack of clean food and water, and, in turn, a compromised gut function. This is 
reflected in two studies, where one investigated the effects of iron addition on the gut microbiota of 
children from Cote d’Ivoire [48], the second study focused on children from South Africa [6]. No 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
detrimental effects of iron supplementation were observed in those that had access to clean water 
and food, yet the children that did not have access to clean water, had adverse side effects.  
We also performed bacterial diversity analysis. α- diversity analysis using the Shannon index, which 
accounts for the distribution and richness of OTUs within a population, showed an increase in 
population diversity at 8 h in the presence of the iron chelator (Figure 3a).  We speculate that the 
chelation of iron may lead to certain taxa exploiting other metals as a means of replacing iron, and 
therefore temporarily facilitating growth in a micronutrient-restricted environment. However, by 24 
h, a visible decrease in diversity was observed under iron-chelated conditions, suggesting an 
exhaustion of these metals and nutrients. β-diversity analysis demonstrated that there was not a 
large range of taxa in common when comparing the control samples to those that were cultured in 
iron-limiting conditions (Figure 3b). Interestingly, at both 8 h and 24 h, there was a shift in β-diversity 
between the two groups. This is in line with a study performed by Dostal et al., [49], which 
investigated the effect of iron on butyrate production in the child gut microbiota, where altering the 
iron concentration in the medium affected microbial community structure as well as causing a shift 
in β-diversity. 
 Microbial metabolic activity contributes to human health. When iron was chelated, we observed a 
decrease in the three main short chain fatty acids (SCFAs) that are produced in the gut (Figure 4), 
which presumably reflects poor growth of fermentative microbes. Based on the 16S rRNA gene 
sequencing data from this study and those published elsewhere, we can infer the potential 
mechanisms behind certain metabolic changes. Firstly, iron-dependent enzymes are critical 
operators of many metabolic pathways, and therefore these processes can be affected by differing 
iron concentrations. Moreover, any microbial fermentation that takes place requires the redox 
balance to be sustained. Due to the dual role of iron as an electron donor and acceptor, we 
speculate that changes in iron levels could have a large effect on redox balance. During the batch 
fermentation, the most prominent effect observed on metabolite production was that of acetate 
levels. Many gut bacteria produce acetate by either the reductive acetyl-CoA pathway, which uses H2 
and CO2 [50], or via the regular glycolytic pathway through pyruvate metabolism [51]. The former 
pathway consists of numerous iron-dependent enzymes and can account for >25% of acetate 
produced in the gut [52]. It is therefore plausible to speculate a lack of conversion of H2 and CO2 to 
acetate under iron-limiting conditions, resulting in an overall decrease in acetate levels. This 
observation also correlated with the viable counts and 16S rRNA gene analysis, where a decrease in 
the members of Bifidobacterium, a prominent bacterial group which produces acetate, was 
observed under iron-limiting conditions. Although correlations of metabolite levels with the relative 
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abundance of bacterial taxa do not provide a causal relationship, it may still provide some 
indications as to which taxa are responsible for any observed differences. 
In conclusion, this in vitro study shows that the chelation of iron, achieved with BPDS, resulted in a 
decrease of the main intestinal SCFAs, a lower relative abundance of potentially pathogenic bacteria 
within the gut microbial community. This observation was also confirmed in pure culture studies 
with pathogenic bacteria. Taken together, these data suggest that iron could provide an 
advantageous niche for potentially pathogenic bacteria and highlights the importance of tight 
control of iron availability to avoid a pathogenic profile within the colon. The relationship between 
iron availability and the human gut microbiome is yet to be fully elucidated, and more extensive 
research on this topic will aid in expanding our knowledge and understanding of this relationship, 
and in extension, help define improved methods for maintaining gut microbial homeostasis. 
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Figure legends 
Figure 1– The effect of iron chelation with BPDS on pure bacterial cultures 
A strain of E. coli isolated from human gut (1A), S. Typhimurium (1B), B. thetaiotaomicron (1C) B. 
longum (1D) and L. rhamnosus (1E) were cultured anaerobically overnight in selective rich media. 
Cultures were supplemented with BPDS, at 0 (control), 10, 20 and 50 µM. Optical density 
measurements were taken every 10 minutes for a period of 24 h and growth curves were plotted for 
each strain. Data shown = mean and are representative of 3 independent experiments. The data was 
statistically analysed using, one-way ANOVA, comparing the different concentrations of BPDS to the 
control, over a period of 24 h; **p<0.01, ****p<0.0001 versus control (0 µM BPDS). 
Figure 2 – Microbial community profiles assessed by 16S rRNA gene analysis 
Microbial composition of both vessels (Control and BPDS). Proportions shown are of the most 
abundant genera (≥0.5%, identification to genus level where possible) identified by sequencing of 
the V4 hypervariable regions of the 16S rRNA gene. Data shown is the average relative abundance 
from the 3 individual experiments from 3 different donors and analysed using the QIIME pipeline. 
SEM values can be found in Table 2.  
Figure 3 – Bacterial diversity profiles of colonic fermentation samples  
(a) α- diversity analysis of batch fermentation samples with (BPDS) and without iron chelator (No 
BPDS) using the Shannon index and (b) β- diversity analysis of batch fermentation samples 
portraying weighted analysis of samples with (BPDS) and without (control) iron chelator using the 
UniFrac metric and presented as a PCoA plot. Data shown is the average Eigenvalues from the 3 
individual experiments from 3 different donors. Each colour represents a different donor. Analysis 
was performed using QIIME (V1.9) and visualised using the XLSTAT add-on package in Microsoft 
Excel. 
Figure 4 – Metabolite concentrations of batch fermentation samples 
Short chain fatty acid concentrations in both vessels were measured using 1H-NMR spectroscopy, 
with samples being screened for multiple metabolites against a spiked standard (TSP) and a 
validated reference library. Data shown is the average ±SEM metabolite concentrations from the 3 
individual experiments from 3 different donors. 
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Table 1 – The effect of iron chelation via BPDS on gut-derived bacterial communities 
Two vessels were set up containing nutritive media and fecal inocula; one vessel was supplemented 
with BPDS (70 μM BPDS) whilst the other was used as a control (0 μM BPDS). Samples were taken 
from each vessel at 0, 8, and 24 h, and then enumerated using selective agar plates. Data shown = 
mean of 3 individual experiments ± SEM. The data was statistically analysed using unpaired t-test, 
assuming unequal variance; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001 for Control versus 
viable counts at the relevant time-point.  
  Viable Counts % (“Control” normalised to 100%, ±SEM) 
Bacterial Group T8 T24 
  Control (+)BPDS Control (+)BPDS 
Total Anaerobes 100 27.83 ±9.47 * 100 29.30 ±7.46 * 
Bacteroides 100 68.71 ±31.61 100 29.70 ±18.47 
Bifidobacteria 100 5.38 ±1.05 *** 100 110 ±106.30 
Clostridia 100 63.58 ±25.84 100 432.89 ±299.18 
Lactobacilli 100 8.21 ±5.10 ** 100 35.47 ±5.92 ** 
Enterobacteriaceae 100 19.01 ±11.19 * 100 17.65 ±15.04 * 
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Table 2 – Proportions of different bacterial taxa (SEM) illustrated in 16S rRNA gene analysis 
 
Taxa 
SEM 
T0 T8 Control T8 BPDS T24 Control T24 BPDS 
g__Bifidobacterium 3.54 6.91 2.09 13.43 6.47 
g__Collinsella 0.66 3.55 1.32 3.49 0.71 
g__Bacteroides 3.17 3.33 10.06 0.80 2.90 
g__Prevotella 5.45 3.07 2.33 0.13 0.30 
f__Rikenellaceae 0.41 0.06 0.32 0.19 0.12 
g__Enterococcus 0.03 0.03 0.03 0.02 1.25 
f__Leuconostocaceae 0.60 0.03 1.97 0.03 3.92 
g__Streptococcus 4.45 0.35 0.19 0.30 15.70 
g__Turicibacter 0.32 0.19 0.15 0.00 0.03 
o__Clostridiales 0.52 0.15 1.83 0.12 0.06 
g__Clostridium 1.38 0.06 0.22 0.06 0.09 
f__Clostridiaceae;g__SMB53 1.56 0.10 0.47 0.17 0.07 
f__Lachnospiraceae 0.30 0.04 0.18 0.29 0.08 
f__Lachnospiraceae 0.54 0.44 1.96 0.55 0.17 
g__Blautia 1.25 2.10 4.19 2.77 0.55 
g__Coprococcus 1.39 2.78 2.17 3.42 0.17 
g__Dorea 0.15 0.64 0.55 0.42 0.28 
g__Lachnospira 0.20 0.00 0.45 0.00 0.00 
g__Roseburia 0.82 0.17 0.85 0.13 0.00 
g__[Ruminococcus] 1.10 1.84 2.66 1.91 1.39 
f__Ruminococcaceae 0.78 0.00 0.70 0.03 0.00 
g__Faecalibacterium 1.66 1.37 5.58 0.35 0.12 
g__Oscillospira 1.69 0.19 0.67 0.44 0.22 
g__Ruminococcus 2.32 0.25 1.75 0.15 0.45 
g__Phascolarctobacterium 0.88 1.15 1.31 0.44 0.21 
g__Veillonella 0.12 0.00 0.03 0.55 0.10 
f__Erysipelotrichaceae 0.34 1.30 0.29 1.23 0.07 
g__Sutterella 0.47 0.93 1.14 0.40 0.73 
f__Enterobacteriaceae 0.37 28.13 25.50 25.70 23.90 
g__Escherichia 16.08 5.86 0.23 2.61 1.72 
g__Klebsiella 0.03 1.36 0.90 1.06 1.17 
g__Akkermansia 7.95 0.22 0.39 0.15 0.21 
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